3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists

US6903131B2 · kind B2 · utility

Assignees

• SCHERING CORPORATION · US
• Pharmacopeia Drug Discovery, Inc. · US

Inventors

• Arthur G. Taveras · Rockaway, US
• Michael P. Dwyer · Scotch Plains, US
• Johan Ferreira · Bethlehem, US
• Viyyoor M. Girijavallabhan · Parsippany, US
• Jianping Chao · Summit, US
• John J. Baldwin · Gwynedd Valley, US
• J. Merritt · Ewing, US
• Ge Li · Shanghai, CN

Key dates

• Filing date: Oct 11, 2002
• Grant date: Jun 7, 2005
• Expiry date: Oct 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.